Arrowhead Gets $120m From GSK For First-In-Class NASH RNAi Candidate
Executive Summary
GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.
You may also be interested in...
GSK Takes Over J&J/Arrowhead Hep B Candidate For Combo Development
Deal Snapshot: Seeking to develop a combination regimen for chronic hepatitis B, GSK acquires rights to J&J/Arrowhead’s siRNA candidate JNJ-3839 to pair with its antisense candidate bepiroversen.
Arrowhead Eager To Take On ‘Straightforward’ NASH Approach Abandoned By J&J
J&J pipeline review results in return of PNPLA3-targeted NASH candidate optioned under 2018 alliance, but the fate of a hepatitis B candidate included in that deal is undetermined so far.
Deal Watch: Lilly Teams With Regor On Metabolic Disorders
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.